Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Science Instruments in laboratory room. Science Research Concept.

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

Artificial intelligence-based model predicts patients’ risk of acute kidney injury

Previous article

High levels of sweet and fruit-flavor chemicals found in ‘tobacco-flavored’ e-cigarette liquids

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News